Replies to post #157152 on Biotech Values

[DewDiligence]

Major FoB Collaborations

[MRK joins Samsung-BIIB collaboratio (which is called Samsung
Bioepis); prior entry for Samsung-BIIB collaboration removed;
entry for MRK-Hanwha Enbrel collaboration also removed
because it was previously terminated.]


Items are shown in reverse chronological order.

 
                  Date   Targets   Geography     iHub References 
 MRK-Samsng/BIIB  2/13   @         unspecified   #msg-84781042, #msg-69629103 
 Catalent-UMN    12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY   6/12   oncology  global        #msg-76359649 
 Daiichi-Coherus  5/12   *         Asia          #msg-75397629 
 Fujifilm-Kyowa   3/12   Humira    unspecified   #msg-73800486 
 ACT-Bioton       2/12   insulin   US & Europe   #msg-74987123 
 ACT-AMGN        12/11   †         global        #msg-70097496, #msg-84340328 
 BAX-MNTA        12/11   various‡  global        #msg-70212854, #msg-70258421 
 HSP-Celltrion   10/09   z         global        #msg-84519981, #msg-77816122 
 MYL-Biocon       6/09   x         global        #msg-72421544, #msg-84561737 
 TEVA-Lonza       1/09   y         global        #msg-34930012  
 Procognia-UTR    n/a    Humira    unspecified   #msg-84340976 

*Enbrel and Rituxan.

†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.

‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.

@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis; Rituxan program terminated (#msg-80622249); presumably excludes FoB’s for BIIB’s branded drugs.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

y Rituxan program terminated (#msg-80236315); status of other programs unknown.

z Eight products: Remicade, Herceptin, Rituxan, Enbrel, Erbitux, Synagis, Humira, Avastin.

[DewDiligence]

MRK/Samsung Bioepis (BIIB) start phase-3 trial of Lantus FoB:

http://in.reuters.com/article/2014/02/10/us-sanofi-merck-idINBREA191FT20140210